...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma

| Print |
Wednesday, 03 March 2010 14:00 (UTC + 1)

invitria_flag_1

For diagnostic and monoclonal antibody production, Zap-Hybridoma improves target antibody purity and Hybridoma productivity

 

Fort Collins, CO March 3, 2010 / b3c newswire / – InVitria’s launch of Zap-Hybridoma provides a powerful solution for hybridoma cell culture.  Zap-Hybridoma was created to improve monoclonal antibody productivity and deliver easier purification of the target product.

Invitria_Zap-Hybridoma

Zap-Hybridoma was developed by InVitria’s Cell Culture Development team as an answer to many of the challenges facing scientists working with hybridoma cell culture. “Not only can Zap-Hybridoma increase productivity, it delivers consistent results and allows hybridoma cells to more quickly adapt away from FBS (fetal bovine serum),” said Dr. Steve Pettit, InVitria’s Director of Cell Culture Development. “We tested Zap-Hybridoma in six of the leading commercial hybridoma media on the market today and observed faster cell growth, a 50% average increase in maximum cell density and increased monoclonal antibody yield when compared to the recommended use of the manufacturer.”

 

“Zap-Hybridoma is an innovation InVitria is proud to bring to its customers so they can achieve better performance more consistently,” said Scott Deeter, InVitria President and CEO. “We developed Zap-Hybridoma to give users an IgG free alternative to FBS without sacrificing performance.”

 

Zap-Hybridoma vs. FBS

 

Zap-Hybridoma

FBS

IgG Free

YES

NO

Consistent

Performance

YES

NO

Defined & Animal

Component-Free

YES

NO

Accelerates

Adaptation to

Serum-Free Media

YES

NO

Lowers Operating

& Capital Costs

YES

NO

 

To order your sample of Zap-Hybridoma or to receive more information, please visit Zap-Hybridoma.

 

 

About InVitria – InVitria.com
InVitria specializes in cell culture media optimization for the biotechnology industry.  InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.
For more information about InVitria’s product solutions, e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311.